2026-01-12 - Analysis Report
**Stock Review Report: Hims & Hers Health Inc (HIMS)**

### Company Overview
Hims & Hers Health Inc is a healthcare technology company that provides online access to prescription medications, wellness products, and telemedicine services.

### Comparison with S&P 500 (VOO)

| Metric | Hims & Hers Health Inc (HIMS) | S&P 500 (VOO) |
| --- | --- | --- |
| Cumulative Return | 103.16% | 72.67% |
| Divergence | 30.50 | N/A |
| Relative Divergence | 27.90% | N/A |

**Analysis:** Hims & Hers Health Inc has significantly outperformed the S&P 500 in terms of cumulative return, showing a divergence of 30.50 points. However, the relative divergence is 27.90%, indicating that the stock is still within a relatively healthy range.

### Alpha, Beta Analysis

| Period | CAGR | MDD | Alpha | Beta | Market Cap (B) |
| --- | --- | --- | --- | --- | --- |
| 2020-2022 | -19.0% | 67.1% | -17.0% | 0.7 | 1.5B |
| 2021-2023 | -65.0% | 67.1% | -66.0% | 1.6 | 2.0B |
| 2022-2024 | 119.0% | 42.0% | 99.0% | 1.7 | 5.5B |
| 2023-2025 | 114.0% | 57.5% | 52.0% | 2.1 | 7.4B |

**Analysis:** The stock has shown significant Alpha (return) in the 2022-2024 period but a large MDD (maximum drawdown) in the 2021-2023 period.

### Stock Price Fluctuations

| Metric | Value |
| --- | --- |
| Close Price | $31.69 |
| Last-Market Close Price | $31.69 |
| Previous Close Price | $33.87 |
| Change | -6.44% |
| 5-day SMA | $34.24 |
| 20-day SMA | $34.82 |
| 60-day SMA | $39.79 |

**Analysis:** The stock has shown a sharp decline in the last market price, indicating a possible fluctuation issue. The 5-day SMA is still above the current price, but the 20-day SMA and 60-day SMA are below the current price.

### RSI, PPO Index Indicators

| Metric | Value |
| --- | --- |
| Market Risk Indicator (MRI) | 0.70 |
| RSI | 35.53 |
| PPO | 0.14 |
| Hybrid Signal | Buy (Cash 0%) |
| Risk Level | Medium |
| 7-day Rank Change | -5 (-) | 
| 7-day Dynamic Expected Return Change | 11.80 (+) |

**Analysis:** The Market Risk Indicator (MRI) is medium, indicating a moderate level of risk. The RSI is low, indicating oversold conditions. The PPO is low, indicating that the price is below the 7-day moving average. The hybrid signal is a buy signal. However, the sharp rebound in the Expected Return indicates a potential fluctuation issue.

### Analyst Opinions

- Key: Hold
- Mean (1=StrongBuy~5=Sell): 2.93
- Opinions: 12
- Target Price (avg/high/low): 43.50 / 85.00 / 25.00

**Analysis:** The analyst consensus is a hold rating with a mean opinion of 2.93. The target price is between 43.50 and 85.00.

### Recent Earnings Analysis

| Date | EPS | Revenue |
| --- | --- | --- |
| 2025-11-03 | 0.07 | $0.60B |
| 2025-08-04 | 0.19 | $0.54B |
| 2025-05-05 | 0.22 | $0.59B |
| 2024-11-04 | 0.35 | $0.40B |
| 2025-11-03 | 0.35 | $0.40B |

**Analysis:** The EPS has shown a mix of positive and negative values in the recent periods. The revenue has shown a decline in the last period.

### Recent News & Significant Events

* Hims & Hers Plunges 39.2% in 3 Months: Time to Hold the Stock or Sell?
* Hims & Hers Health: Capitalizing On Healthcare Innovation
* Hims & Hers Health stock falls after Amazon Pharmacy adds Wegovy pill
* HIMS Stock Falls after BofA Slashes Price Target to a Street-Low of $29
* Hims & Hers: Looking Beyond GLP-1s To The Next Phase Of Global Growth
* Hims & Hers Growth Story Has A Lot To Prove In 2026

**Analysis:** The stock has seen a sharp decline in the last 3 months. Several analysts have expressed concerns about the stock's growth prospects.

### Financial Information

**Revenue and Profitability**

| Quarter | Revenue | Profit Margin |
| --- | --- | --- |
| 2025-09-30 | $0.60B | 73.80% |
| 2025-06-30 | $0.54B | 76.39% |
| 2025-03-31 | $0.59B | 73.50% |
| 2024-12-31 | $0.48B | 76.81% |
| 2024-09-30 | $0.40B | 79.16% |

**Capital and Profitability**

| Quarter | Equity | ROE |
| --- | --- | --- |
| 2025-09-30 | $0.58B | 2.72% |
| 2025-06-30 | $0.56B | 7.55% |
| 2025-03-31 | $0.55B | 9.01% |
| 2024-12-31 | $0.48B | 5.46% |
| 2024-09-30 | $0.44B | 17.18% |

**Analysis:** The revenue has shown a mix of values in the recent periods. The profit margin has been high in some periods but declined in others. The ROE has shown a decline in several periods.

**Comprehensive Analysis:**

The stock has shown significant fluctuations in recent months, with a sharp decline in the last market price. The RSI and PPO indicators are oversold, and the hybrid signal is a buy signal. However, the sharp rebound in the Expected Return indicates a potential fluctuation issue. The analyst consensus is a hold rating, but several analysts have expressed concerns about the stock's growth prospects. The revenue and profit margin have shown a mix of values in the recent periods. Overall, the stock's performance is subject to high volatility, and investors should exercise caution before making any investment decisions.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.